Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
There is another rather entertaining, 10-minute video today on the Medscape Oncology web site showing a conversation between Dr. Matt Cooperberg of the University of California, San Francisco and Dr. Andrew Vickers of the Memorial Sloan-Kettering Cancer Center in New York. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: outcome, quality, radical prostatectomy, surgery | Leave a Comment »
According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active surveillance, age, expectancy, life, monitoring, mortality, risk | 5 Comments »
As regular readers will be well aware, the implementation of varying types of androgen deprivation therapy (ADT) in hormone-sensitive and in castration-resistant forms of progressive prostate cancer is evolving. Five or so years from now we may be looking at a very different set of ways to use ADT than those we have been used to. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, castration-resistant, CRPC, deprivation | Leave a Comment »
Many readers of this web site may be interested in a video discussion on the Medscape web site between two relatively young urologists about the implications of the Prostate Outcomes Outcomes Study (PCOS), on which we commented a few months back. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: chronic, disease, Management, outcome, PCOS, risk | 1 Comment »
According to an article in The Sunday Times in the UK over the weekend, a well-known surgeon in the UK is claiming to have carried out “the first” radical prostatectomy on a man with no other indicator for treatment except a BRCA2 mutation and a significant family history of breast and prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: BRCA1, BRCA2, prophylactic, risk, surgery, Treatment | 3 Comments »
There is an interesting editorial just published on line in the Journal of Urology and written by Prof. Joseph Smith of Vanderbilt University. Unfortunately, because it is an editorial, there is no abstract, and the text is only accessible if you are a subscriber to the journal. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: da Vinci, responsibility, robot, trust | 8 Comments »
According to data to be presented at the upcoming meeting of the American Society of Clinical Oncology (ASCO), enzalutamide monotherapy substantially reduces PSA levels in androgen deprivation therapy (ADT)-naive patients with progressive or high-risk disease (including men with evident metastases). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, enzalutamide, first line, outcome, PSA | 2 Comments »
Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, BRCA1, BRCA2, olaparib | 2 Comments »
In April 2012 we had noted that Tokai Pharmaceuticals was planning to initiate a Phase II trial of its investigational drug galeterone (also known as TOK-001) in the treatment of men with castration-resistant prostate cancer (CRPC). The company has now announced that it has the funding to expand enrollment in this Phase II trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, galeterone, TOK-001, trial | Leave a Comment »
A new paper recently published on line in Urology (“the Gold Journal”) suggests that men with diabetes who are treated with curative intent for localized prostate cancer using external beam radiation therapy may experience higher than normal risk for late genitourinary complications and adverse effects. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: diabetes, external beam, localized, radiation | Leave a Comment »
Last September we asked whether the Oncotype DX test for risk of prostate cancer developed by Genomic Health was “ready for prime time”. In a media release issued earlier this week, the company said that it was. However, there are a number of unresolved issues that are likely to impact the uptake of this new test. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Tagged: DX, Oncotype, risk, significant | 4 Comments »
So the American Urology Association (AUA) is clearly “on a roll” when it comes to guidance on the detection and management of prostate cancer. This is the third new guidance document issued in a matter of days. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: adjuvant, guideline, radiation therapy, radical prostatectomy, salvage | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site